Mentions
Extended reach
Total likes
Video views
AI synopsis
Participants show high interest and moderate engagement by discussing key trials like the IDEA collaboration and the implications of shorter therapy durations for patients, using technical language and references to clinical factors, which indicates they see this research as impactful for treatment decisions and patient outcomes.
Most discussions recognize the findings of the article, noting the lack of significant difference between 3 and 6 months of therapy for certain treatments, indicating general agreement with the conclusions.
The discussions consistently highlight the importance of treatment duration, prognosis, and implications for clinical practice, demonstrating high engagement and interest.
Participants reference specific clinical trials and data, discussing nuances in treatment outcomes and prognostic factors, showing moderate to deep engagement.
The conversations touch on potential changes to treatment protocols and emphasize the significance of the findings for patient care, suggesting a meaningful impact on medical practice.
@cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA trial has demonstrated no difference in OS for most patients with stage III disease receiving 3 months of adjuvant chemo vs 6 months. Shorter duration of chemo = less toxicity https://t.co/975eM6gokf.
@SeanLangenfeld Not a “surgical” paper, but @agrothey paper on Duration of Adjuvant Therapy for Stage III colon cancer in @NEJM might be an interesting choice. https://t.co/975eM6gokf
【Xenobots Journal Club】
1/2 IDEA Collaboration: prospective, preplanned, pooled analysis of six randomized, phase 3 trials showed that there was no statistically significant benefit of 6 months of CAPOX vs 3 months of CAPOX in patients with stage III colon cancer https://t.co/47DmuWdgPu
Dr. Axel Grothey @agrothey from @west_cancer is presenting on #colorectalcancer at our #GICancer #GISM conference THIS Sunday! Earn #CME ! Register at https://t.co/uXNFLwXJYn Check out some projects he's contributed to: 1. https://t.co/C8zH7V10JG 2. https://t.co/Nr1XZRhtkL https://t.co/2bgW6PxTrT
@NorikaLaivadeta Např. zde je srovnatelná adjuvantní terapie u stage III s horšími výsledky oproti pohybu: https://t.co/hNeNc3F7CP
This video discusses clinical cases on adjuvant therapy for stage III colon cancer, exploring recent scientific data and best practices to optimize treatment outcomes and reduce toxicity.
This video features oncologists Dr. Angelo Bezerra, Dr. Marcos Camandaroba, and Dr. Daniel Saragiotto discussing a clinical case on adjuvant treatment for stage III colon cancer. They explore recent scientific data and…
Oncologists Dr. Angelo Bezerra, Dr. Marcos Camandaroba, and Dr. Daniel Saragiotto discuss an in-depth clinical case on adjuvant treatment for stage III colon cancer, focusing on recent scientific data and therapeutic…
RT @Milosval1: @NorikaLaivadeta Např. zde je srovnatelná adjuvantní terapie u stage III s horšími výsledky oproti pohybu: https://t.co/hNe…
@NorikaLaivadeta Např. zde je srovnatelná adjuvantní terapie u stage III s horšími výsledky oproti pohybu: https://t.co/hNeNc3F7CP
@vishalsethi_cv @liensofnewyork No stat. difference between 3mth/6mth. https://t.co/lJYxR0x04o So what can we conclude? That it has achieved its maximum effect within 3 months? That tolerance develops within 3 months? That no difference because it doesn't do *anything* i.e. framing based on prior knowledge.
Currently, the treatment of pMMR locally advanced colon cancer (LACC) is based on adequate oncological surgery
RT @web8xen: 【Xenobots Journal Club】
【Xenobots Journal Club】
@gsyblue @guildsman @ranj585 @TumorBoardTues @colontown With T3N2a & if your tumor does not have high risk features, I am not sure why you need to get 8 cycles of CAPOX. Please read these as well 1) https://t.co/wnxRRgSPXa 2)https://t.co/ZboL7vNNW3
Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients https://t.co/0AAlnWSn1J
Data Support Shorter Duration of Adjuvant Chemotherapy for Stage III Colon Cancer https://t.co/LLKmQdj2np
1/2 IDEA Collaboration: prospective, preplanned, pooled analysis of six randomized, phase 3 trials showed that there was no statistically significant benefit of 6 months of CAPOX vs 3 months of CAPOX in patients with stage III colon cancer https://t.co/47DmuWdgPu
RT @merchea_md: @cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA tri…
RT @merchea_md: @cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA tri…
RT @merchea_md: @cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA tri…
RT @merchea_md: @cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA tri…
@cmf2x @jendavidsmd @SAGES_Updates @ASCRS_1 @justinmaykel @juliomayol @SeanLangenfeld @marklewismd Fortunately the IDEA trial has demonstrated no difference in OS for most patients with stage III disease receiving 3 months of adjuvant chemo vs 6 months. Shorter duration of chemo = less toxicity https://t.co/975eM6gokf.
RT @btfoundation: Dr. Axel Grothey @agrothey from @west_cancer is presenting on #colorectalcancer at our #GICancer #GISM conference THIS Su…
Dr. Axel Grothey @agrothey from @west_cancer is presenting on #colorectalcancer at our #GICancer #GISM conference THIS Sunday! Earn #CME ! Register at https://t.co/uXNFLwXJYn Check out some projects he's contributed to: 1. https://t.co/C8zH7V10JG 2. https://t.co/Nr1XZRhtkL https://t.co/2bgW6PxTrT
@winsoncheung @OncOutcomes @batraatul85 5 of these 6 adjuvant studies included patients older than age 75. https://t.co/ktRnLFJHe6
@venkmurthy @VPrasadMDMPH The populations don't make sense in this eg and should not be meta-analysed in first place. But IDEA provides a stat framework eg for interpretation when such a method is used properly. https://t.co/ktRnLFJHe6
RT @merchea_md: @SeanLangenfeld Not a “surgical” paper, but @agrothey paper on Duration of Adjuvant Therapy for Stage III colon cancer in @…
RT @merchea_md: @SeanLangenfeld Not a “surgical” paper, but @agrothey paper on Duration of Adjuvant Therapy for Stage III colon cancer in @…
@SeanLangenfeld Not a “surgical” paper, but @agrothey paper on Duration of Adjuvant Therapy for Stage III colon cancer in @NEJM might be an interesting choice. https://t.co/975eM6gokf